BioSyent Releases Q2 and H1 2023 Financial Results
August 22, 2023 16:15 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 22, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2023. Key...
BioSyent Declares Third Quarter 2023 Dividend
August 22, 2023 16:01 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 22, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent Schedules Q2 and H1 2023 Earnings Release for August 22, 2023
August 15, 2023 16:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 15, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30,...
BioSyent lance Inofolic® pour les femmes atteintes du syndrome des ovaires polykystiques (SOPK)
August 08, 2023 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, 08 août 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », titre à la Bourse de croissance TSX : RX) a le plaisir d’annoncer que sa filiale, BioSyent Pharma Inc., a...
BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
August 08, 2023 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 08, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first...
BioSyent Pharma to Introduce Gelclair® at AHNS 11th International Conference on Head and Neck Cancer
July 06, 2023 17:53 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, July 06, 2023 (GLOBE NEWSWIRE) -- BioSyent Pharma Inc. (“BioSyent Pharma”), a subsidiary of BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX), is attending the...
BioSyent Announces Long-term Extension of Cathejell® Agreement
June 20, 2023 08:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, June 20, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc....
BioSyent Announces Approval of New Product
May 31, 2023 17:42 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 31, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has received...
BioSyent Releases Financial Results for Q1 2023
May 26, 2023 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 26, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2023. Key highlights...
BioSyent Declares Second Quarter 2023 Dividend
May 25, 2023 17:40 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 25, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...